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Abstract. Chemotherapy for lymphoma may be avoided in the 
presence of coincident cytopenia. In case of immune cytopenia 
secondary to lymphoma, treatment of cytopenia is the same for 
primary cases, however, chemotherapy for lymphoma may be 
effective at the cost of severe hematological toxicity. The present 
study reports a complex case of thrombocytopenia and direct 
antiglobulin test-negative hemolytic anemia, thus mimicking 
Evans syndrome, secondary to cluster of differentiation 5-posi-
tive B-cell lymphoma with massive splenomegaly, in a patient 
suffering from rheumatoid arthritis for two decades. Treatment 
with prednisolone, high-dose dexamethasone, eltrombopag and 
rituximab for cytopenia were not effective. Chemotherapy with 
bendamustine subsequently resolved the cytopenia, addition-
ally resulting in a complete remission of lymphoma. Thus, 
bendamustine may have a role in the management of lymphoma 
complicated with severe cytopenia.
Introduction
Autoimmune diseases including rheumatoid arthritis are asso-
ciated with a higher risk of non-Hodgkin lymphoma (1) and 
the frequency of autoimmune disease in lymphoma patients 
was 8.2% (2). Among autoimmune diseases, combination 
of immune thrombocytopenia and autoimmune hemolytic 
anemia, which is known as Evans syndrome, may precede 
lymphoma (3,4). Treatment of these cytopenias is the same for 
primary cases although coincident presence of lymphoma is 
a clinical problem. Conventional chemotherapy of lymphoma 
may be avoided in the presence of severe cytopenia because 
of the increased risk of hematological toxicity, however, treat-
ment of lymphoma may be needed for the few patients with 
lymphoma-associated cytopenia.
In the present study, we report a complex case of thrombo-
cytopenia and hemolytic anemia secondary to CD5-positive 
B-cell lymphoma in a patient with massive splenomegaly and 
rheumatoid arthritis, which responded to chemotherapy with 
bendamustine.
Case report
The present study focused on a 67-year-old Japanese woman 
who developed splenomegaly and mild neutropenia after a 
20-year course of rheumatoid arthritis which had been in 
remission with tofacitinib treatment. In addition, she developed 
thrombocytopenia and anemia and tofacitinib was terminated. 
Laboratory examination revealed the followings: Reticulocyte 
248x109/l, total bilirubin 1.9 mg/dl, lactic dehydrogenase (LDH) 
438 U/l (upper normal limit 223 U/l), direct anti-globulin test 
(DAT) negative and platelet-associated immunoglobulin G 
123 ng/107 cells (upper normal limit 46). Peripheral blood 
smear rarely showed fragmented red cells and there was no 
coagulopathy. Bone marrow aspirate and needle biopsy showed 
erythroid hyperplasia and no definite lymphoma infiltrates but 
several reactive lymphocyte aggregates. Tentative diagnosis of 
immune thrombocytopenia (ITP) and DAT-negative hemolytic 
anemia, thus DAT-negative Evans syndrome, was made in 
spite of massive splenomegaly. Prednisolone 30 mg/day was 
administered to treat bicytopenia while abnormal lymphocytes 
appeared in peripheral blood (Fig. 1). Flow cytometric analysis 
showed the presence of monoclonal B-cells expressing CD5, 
CD19, CD20, HLA-DR, and surface IgM-λ and partially positive 
for CD10 without CD23 expression. In addition, fluorescence 
in situ hybridization analysis of peripheral blood revealed 
an increased number of MYC and IGH signals without any 
fusion in 40% of mononuclear cells examined, corroborating 
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the result of bone marrow cytogenetics which revealed later 
that 2 out of 20 cells were near-tetraploid cells with complex 
cytogenetics. Diagnosis of CD5-positive B-cell lymphoma 
was made. 18F‑fluorodeoxyglucose (FDG) positron emission 
tomography (PET)-computed tomography (CT) showed massive 
splenomegaly with high uptake of FDG as well as diffuse 
FDG uptake in both lungs and the bone marrow without any 
abnormal lung shadow in CT (Fig. 2A), suggesting intravascular 
large B-cell lymphoma; hypoxemia developed with peripheral 
oxygen saturation 88% (room air). Severe thrombocytopenia 
(platelet count <10x109/l) refractory to platelet transfusion 
developed and hindered diagnostic splenectomy or splenic 
biopsy for histological determination of lymphoma. We 
administered high-dose dexamethasone, high-dose γ-globulin 
and rituximab along with daily platelet transfusions and 
semi-weekly red blood cell transfusions to treat both severe 
bicytopenia and lymphoma. A transient decrease in number of 
lymphoma cells in the peripheral blood was observed after each 
dose of rituximab, however, no improvement of bicytopenia 
occurred. We administered second high-dose dexamethasone 
followed by prednisolone maintenance and start of eltrombopag 
12.5 mg/day, which was planned to be escalated weekly by 
Figure 1. Abnormal lymphoid cells in the peripheral blood. (A-D) These cells were positive for CD5, CD19, CD20, HLA-DR, and surface IgM-λ, partially 
positive for CD10, and negative for CD23 except for a neutrophil in D.
Figure 2. PET-CT scans. (A) Massive splenomegaly and hepatomegaly with high FDG uptakes in addition to diffuse FDG uptake in both lungs and bone 
marrow were found before chemotherapy. (B) Hepatosplenomegaly and FDG uptakes disappeared after chemotherapy.
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12.5 mg per day up to 50 mg per day. Even after 3 doses of 
rituximab, the number of peripheral blood lymphoma cells 
increased as well as serum levels of LDH as shown in Fig. 3A. 
Then, we administered bendamustine 90 mg/m2 once. Due to 
high serum levels of total bilirubin (8.8 mg/dl), second dose of 
bendamustine was omitted. Severe pancytopenia developed; 
leukocytes 1.9x109/l, hemoglobin 3.7 g/dl, and platelets 3x109/l 
at nadir of bone marrow suppression (Fig. 3B and C). Three 
weeks later, transfusion-independence for both of erythrocytes 
and platelets was obtained while cytomegalovirus antigenemia 
had become positive and severe pneumonia had developed. 
Antiviral, antibiotic and antifungal treatments were administered 
successfully to overcome these complications. Spleen decreased 
in size and pancytopenia ultimately disappeared as well as 
lymphoma cells in the peripheral blood. She received additional 
5 courses of bendamustine plus rituximab therapy in full 
doses (5) and PET-CT scans revealed complete disappearance 
of FDG uptakes and splenomegaly (Fig. 2B).
The patient has provided her consent regarding the publi-
cation of the case details. The present study was undertaken 
according to a project of clinical surveillance in Tottori University 
Hospital, which was approved by the Ethics Committee at 
Tottori University Faculty of Medicine (approval no. 2489).
Discussion
Massive splenomegaly may constitute the initial presentation 
of lymphoma. In the subset of patients in which splenomegaly 
remains unexplained, lymphomas account for the leading 
cause and splenectomy is required for a definitive diagnosis 
although primary effort must be taken to achieve diagnosis 
by integrating presenting clinical and laboratory data with 
imaging, peripheral blood, bone marrow assessment, thus 
trying to avoid splenectomy for diagnostic purposes (6). In 
the current case, bone marrow examination gave no definitive 
diagnosis and severe thrombocytopenia hindered diagnostic 
splenectomy while CD5-positive monoclonal B cells with 
bizarre morphology and complex cytogenetics appeared in the 
peripheral blood. Taken splenomegaly and diffuse pulmonary 
involvement as suggested by the PET-CT scan into consid-
eration, pulmonary intravascular large B-cell lymphoma is 
probable diagnosis (7,8).
Evans syndrome is a rare disease characterized by the 
simultaneous and sequential development of autoimmune 
hemolytic anemia and ITP and/or immune neutropenia. 
Michel et al analyzed the data from 68 patients with Evans 
syndrome including 3 DAT-negative cases (4). Half of the 
patients were associated with an underlying disorder including 
lymphoproliferative disorders and two patients with B-cell 
non-Hodgkin lymphoma was included (4). The presence of 
massive splenomegaly suggested against autoimmune mecha-
nisms underlying bicytopenia in the current case although 
the severity of bicytopenia refractory to multiple transfusions 
could not negate the presence of immune dysregulation like 
Evans syndrome especially because the patient suffered from 
rheumatoid arthritis. Whether it was via immunological 
Figure 3. Time courses of (A) CD5-positive lymphoma treated with bendamustine and rituximab, (B) hemolytic anemia and (C) thrombocytopenia. 
(A) Peripheral blood lymphoma cell numbers (%) and serum LDH levels (U/l) are shown over time and correlated well. (B) Reticulocyte counts (%) and 
hemoglobin levels (g/dl) are shown over time. (C) Platelet counts are shown as a logarithmic scale. The size of each circle and thickness of each line reflect the 
relative doses of the indicated drugs. The first dose of rituximab was split in two because of splenomegaly. A vertical line in the middle indicates the time of 
the initial bendamustine administration, which was given only one day because of severe jaundice. Each red blood cell transfusion, derived from 400 ml blood, 
is shown as a diamond and each platelet transfusion, derived from 2,000 ml blood, as a triangle.
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mechanisms or not, severe bicytopenia was a clinical problem 
confronting lymphoma progression. Park et al reported 
a case of DAT-negative Evans syndrome associated with 
diffuse large B-cell lymphoma, in which cytopenia preceded 
lymphoma and R-CHOP chemotherapy was effective (3). 
Multirefractory ITP is a serious and potentially life-threat-
ening condition although chemotherapy may be needed for 
the few patients with ITP secondary to lymphoma (9). In the 
current case, prednisolone, high-dose γ-globulin, high-dose 
dexamethasone, rituximab and eltrombopag failed to increase 
platelet counts and hemoglobin levels. In addition, periph-
eral lymphoma cells increased in number and serum levels 
of LDH elevated despite repeated rituximab doses. Then, 
administration of bendamustine successfully eradicated 
lymphoma cells from the peripheral blood and increased 
platelet counts. Furthermore, anemia, although transiently 
aggravated, ultimately disappeared. Bendamustine is effective 
for indolent and mantle cell lymphoma (5) and even aggressive 
lymphoma (10,11). Bendamustine plus rituximab was better 
tolerated than R-CHOP with lower rates of myelotoxicity while 
higher frequency of grade 3-4 lymphocytopenia was seen in 
the bendamustine plus rituximab group (5). Bendamustine 
may be favored for patients with lymphoma associated with 
severe cytopenia because of less myelotoxicity. Furthermore, 
lymphotoxicity of bendamustine may affect autoimmune cyto-
penia favorably.
In conclusion, we here report a complex case of severe 
bicytopenia and B-cell lymphoma in a patient with rheuma-
toid arthritis. Bendamustine was successful for both diseases 
and may be preferred in case of lymphoma complicated with 
cytopenia.
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